BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33122421)

  • 1. Angiographic control versus ischaemia-driven management of patients undergoing percutaneous revascularisation of the unprotected left main coronary artery with second-generation drug-eluting stents: rationale and design of the PULSE trial.
    De Filippo O; Bianco M; Tebaldi M; Iannaccone M; Gaido L; Guiducci V; Santarelli A; Zaccaro L; Depaoli A; Vaudano P; Quadri G; Gagnor A; Boccuzzi G; Solitro F; Cortese G; Guarnaccia C; Tore D; Veltri A; Franchin L; Angelini F; Garbo R; Giammaria M; Varbella F; Marchisio F; Fonio P; De Ferrari GM; Cerrato E; Campo G; D'Ascenzo F
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33122421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries.
    D'Ascenzo F; Gaido L; Bernardi A; Saglietto A; Franzé A; Ielasi A; Trabattoni D; Di Biasi M; Infantino V; Rognoni A; Helft G; Gangor A; Latini RA; De Luca L; Mitomo S; Ugo F; Smolka G; Huczek Z; Cortese B; Capodanno D; Chieffo A; Piazza F; di Mario C; Poli A; D'Urbano M; Romeo F; Giammaria M; Varbella F; Sheiban I; Escaned J; De Ferrari GM
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):522-529. PubMed ID: 31385427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Planned angiographic control versus clinical follow-up for patients with unprotected left main stem stenosis treated with second generation drug-eluting stents: A propensity score with matching analysis from the FAILS (failure in left main with second generation stents-Cardiogroup III Study).
    D'Ascenzo F; Iannaccone M; Pavani M; Kawamoto H; Escaned J; Varbella F; Boccuzzi G; Hiddick-Smith D; Colombo A; Gaita F
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):E271-E277. PubMed ID: 29130573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DELTA 2 Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents in Patients With Obstructive Left Main Coronary Artery Disease.
    Chieffo A; Tanaka A; Giustino G; Briede I; Sawaya FJ; Daemen J; Kawamoto H; Meliga E; D'Ascenzo F; Cerrato E; Stefanini GG; Capodanno D; Mangiameli A; Templin C; Erglis A; Morice MC; Mehran R; Van Mieghem NM; Nakamura S; De Benedictis M; Pavani M; Varbella F; Pisaniello M; Sharma SK; Tamburino C; Tchetche D; Colombo A;
    JACC Cardiovasc Interv; 2017 Dec; 10(23):2401-2410. PubMed ID: 29217002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
    Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
    Giustino G; Mastoris I; Baber U; Sartori S; Stone GW; Leon MB; Serruys PW; Kastrati A; Windecker S; Valgimigli M; Dangas GD; Von Birgelen C; Smits PC; Kandzari D; Galatius S; Wijns W; Steg PG; Stefanini GG; Aquino M; Morice MC; Camenzind E; Weisz G; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Chieffo A; Mehran R
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1890-901. PubMed ID: 27659564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic and Clinical Outcomes After Everolimus-Eluting Stenting for Unprotected Left Main Disease and High Anatomic Coronary Complexity.
    Migliorini A; Valenti R; Parodi G; Vergara R; Buonamici P; Cerisano G; Carrabba N; Antoniucci D
    JACC Cardiovasc Interv; 2016 May; 9(10):1001-7. PubMed ID: 27198680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta blockers versus calcium channel blockers for provocation of vasospastic angina after drug-eluting stent implantation: a multicentre prospective randomised trial.
    Sawano M; Katsuki T; Kitai T; Tamita K; Obunai K; Ikegami Y; Yamane T; Ueda I; Endo A; Maekawa Y; Kawamura A; Fukuda K; Kohsaka S
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33087441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery.
    Cavalcante R; Sotomi Y; Zeng Y; Lee CW; Ahn JM; Collet C; Tenekecioglu E; Suwannasom P; Onuma Y; Park SJ; Serruys PW
    Heart; 2017 Mar; 103(6):428-433. PubMed ID: 27651390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a Simple Angiographic Approach With a Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Score-Based Approach for Left Main Coronary Artery Stenting: A Pooled Analysis of Serial PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease) Studies.
    Lee PH; Lee JY; Lee CW; Kim SO; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Park SJ
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005374. PubMed ID: 29311287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of QFR Measured Immediately After Successful Stent Implantation: The International Multicenter Prospective HAWKEYE Study.
    Biscaglia S; Tebaldi M; Brugaletta S; Cerrato E; Erriquez A; Passarini G; Ielasi A; Spitaleri G; Di Girolamo D; Mezzapelle G; Geraci S; Manfrini M; Pavasini R; Barbato E; Campo G
    JACC Cardiovasc Interv; 2019 Oct; 12(20):2079-2088. PubMed ID: 31563688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.